51 results about "Tumor resistance" patented technology

The invention provides an alkaloid compound as well as a preparation method and an application thereof in tumor resistance. The alkaloid compound provided by the invention shows a remarkable cytotoxic effect on human non-small cell lung cancer cells A549, mouse lung adenocarcinoma cells Lewis, human triple negative breast cancer cells MDA-MB-231 and mouse breast cancer cells 4T1, and can be used for preparing medicines for treating breast cancer, lung cancer and the like.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a tetravalent platinum compound as well as a preparation method and application thereof. The invention provides a tetravalent platinum compound. The tetravalent platinum compound has a structure shown as a formula a to a formula d, wherein linker is respectively connected with a Pt-containing mother nucleus and a PARP inhibitor through-O-C = O; the PARP inhibitor comprises a carboxyl-containing structure and a carboxyl-free structure; when the PARP inhibitor contains a carboxyl structure, the linker is when the PARP inhibitor does not contain the carboxyl structure, and the data of the linker as the embodiment shows that the tetravalent platinum compound provided by the invention has good anti-tumor activity and low tumor drug resistance when being used as the PARP inhibitor.

This invention relates to the application of exosomes in reversing tumor resistance to immune checkpoint (PD-1) inhibitors. A novel application of exosomes in the preparation of pharmaceutical compositions reversing tumor resistance to immune checkpoint inhibitors is disclosed. Exosomes generated from tumor cells recombinantly expressing adenylate cyclase 7 (ADCY7) can significantly reverse tumor resistance to PD-1 inhibitors, and the exosomes exhibit a synergistic effect with the PD-1 inhibitors.

The invention relates to the technical field of medical chemistry and tumor treatment, in particular to application of a novel NOX4 inhibitor ZZU026 and derivatives thereof in tumor resistance and immune response change. The preparation method of the ZZU026 comprises the following steps: replacing N, N-dimethylamino on a benzene ring of GKT137831 with morpholinyl; methoxyl is introduced into the core skeleton. The ZZU026 has a remarkable inhibiting effect on NOX4, has the functions of inhibiting tumor growth, new vascularization and immune-related diseases, regulating and controlling polarization of macrophages and the like, and can inhibit phenotype transformation of macrophages from M1 to M2 and finally inhibit proliferation and immune escape of lung cancer cells; the ZZU026 and the derivatives thereof can be prepared into drugs, health care products, tablets, particles, capsules, oral liquid or injection, and can be used for treating lung cancer and other tumors.

The invention belongs to the technical field of cancer immunotherapy, and particularly relates to iterative radiation-resistant tumor cell debris, a preparation method thereof and an application thereof in tumor resistance. The anti-radiation tumor cells generated by repeated radiation exposure show higher TMB (Tetramethylbenzidine) and induce stronger immunoreaction, so that a personalized vaccine is developed based on the method, and the frozen fragment vaccine is obtained by freeze thawing and inactivation of the radiation-resistant tumor cells. The RR-FDV exhibits enhanced immunogenicity as compared to a conventional radiosensitive counterpart. In the present disclosure, RR-FDV exhibits superior activation of antigen presenting cells, while in vivo, it recruits more dendritic cells to the vaccination site, promotes DC-mediated antigen presentation, and induces stronger antigen-specific T cell toxicity.

The invention discloses an application of an ARRB1 inhibitor in preparation of a tumor drug resistance reversal agent or a tumor drug sensitizer. It is found that by reducing ARRB1 expression, the sensitivity of human breast cancer cells to etoposide can be improved, the drug resistance of breast cancer etoposide can be reversed, and an ARRB1 inhibitor can be combined with an anti-tumor drug etoposide for use to improve the treatment effect. The invention provides a new direction for research and development of drugs for overcoming breast cancer treatment drug resistance, and has important clinical application value and development value.

The invention relates to the field of biological medicines, in particular to application of an MAGEB16 regulator in preparation of products for treating autoimmune diseases or resisting tumors. The invention provides an application of an MAGEB16 regulator in preparation of a product for treating autoimmune diseases or resisting tumors. The invention also provides an antibody combined with the surface of a tumor cell or an antigen binding fragment thereof. The application finds that the MAGEB16 protein can be expressed on the surface of a tumor cell, so that the technical scheme of directly targeting the MAGEB16 on the surface of the tumor cell through an antibody or a nucleic acid molecule and a series of technical schemes of targeting the MAGEB16 on the surface of the tumor cell become feasible technical schemes, and a new technical scheme is provided for efficient tumor resistance.

The present application relates to the application of a glyceroglycolipid compound Gingerglycolipid B in the field of biochemical application technology in the preparation of a tumor resistance reversal agent or a tumor drug sensitizer. The structure of the glyceroglycolipid compound Gingerglycolipid B is shown as follows: #imgabs0# The drug resistance or tumor drug is doxorubicin. Studies have shown that the compound has the ability to reverse MCF-7 / ADR activity when used in combination with doxorubicin at concentrations of 5, 10, and 20 μg / mL, respectively.

The invention relates to construction and application of nanoparticles taking black rice-derived beta glucan as a carrier. The construction comprises the following steps: 1) extracting black rice polysaccharide; 2) purifying black rice polysaccharide; 3) folic acid modification; and (4) preparing the nano-particles. The black rice-derived polysaccharide prepared by the construction method has few branches, the black rice-derived few-branch beta-glucan is applied to the field of drug delivery for the first time, and the modified beta-glucan is used for carrying antitumor drugs, so that a drug carrying system has dual effects of tumor resistance and tumor immunotherapy and a targeting effect at the same time.

The invention relates to wild phellinus igniarius SH-27 fermentation liquor rich in polyphenol and application of the wild phellinus igniarius SH-27 fermentation liquor, and belongs to the technical field of biological fermentation. The screened wild phellinus igniarius SH-27 contains rich active ingredients, the polyphenol content of mycelium pellets subjected to liquid culture of the wild phellinus igniarius SH-27 is 29.74 mg / g, the triterpene content is 3.52 mg / g, the polysaccharide content is 88.61 mg / g, the flavone content is 5.14 mg / g, and the average yield of polyphenol metabolites in fermentation liquor reaches 33.72 mg / L. By optimizing a liquid culture medium, the polyphenol content of the mycelium pellets can reach 46.98 mg / g, and the yield of the polyphenol metabolites in the fermentation liquor can reach 46.98 mg / g. A metabolite of the compound has huge medicinal potential in the aspects of treatment and intervention of oxidation resistance, inflammation resistance, cancer resistance, tumor resistance, diabetes and hypertension and the like. According to the method, the yield of the phellinus igniarius polyphenol metabolites is improved through optimization of a PSO-BP neural network model, and the average yield reaches 33.72 mg / L and is improved by 33.5% compared with fermentation liquor obtained under the single-factor experiment condition.

The invention belongs to the field of medicines, and particularly discloses a pharmacodynamic active phenol chemical modified cis-platinum material which is at least one compound with a structural general formula 1, namely imgabs0 #. The invention also discloses preparation and application of the material. The method provided by the invention can effectively reduce toxicity and can synergistically improve the drug effect performance.

The invention belongs to the technical field of biological medicines, and particularly relates to a tumor microenvironment response type nano-drug based on linear-dendritic polymers. The preparation method comprises the following steps: connecting a dendritic fragment to a polymer skeleton through an enzyme-cleavable peptide chain, and coupling a chemotherapeutic drug to a dendritic periphery through a pH-unstable hydrazone bond to obtain an amphiphilic polymer prodrug; the stable nanoparticles are obtained by screening polymeric monomers, can be efficiently taken by tumor cells, and have advantages in tumor tissue penetration and tumor resistance; the polymer prodrug can also load an adenosine receptor antagonist drug to prepare a nano-drug, and the nano-drug reverses adenosine-mediated immunosuppression to realize a synergistic effect of the adenosine receptor antagonist drug and a chemotherapeutic drug; the nano-drug and the PD-1 antibody cooperate to further improve the immune response in vivo and the anti-TNBC effect. The polymer prodrug and nano-drug synthesized by the invention have good prospects in the aspect of treating TNBC.

The invention discloses a recombinant fusion protein and application thereof in preparation of anti-gastric cancer angiogenesis medicines, and relates to the technical field of biological medicines. The amino acid sequence of the recombinant fusion protein is as shown in SEQ ID NO. 1. According to the invention, the amino acid sequence of the gastric cancer vascular targeting peptide CNTGSPYEC and the potent vascular inhibitor Endostatin gene are recombined to construct the recombinant fusion protein, and the selective distribution capability of the targeting peptide is utilized to carry the anti-vascular drug Endostatin to be more specifically enriched in gastric cancer vascular endothelial cells, so that the anti-vascular effect and the anti-tumor effect are improved, and the tumor resistance of the gastric cancer vascular targeting peptide CNTGSPYEC is improved. Meanwhile, due to the fact that distribution of Endostatin in normal blood vessels and tissues is reduced, corresponding toxic and side effects can be reduced, and great significance is achieved for improving the current situation of gastric cancer anti-blood-vessel treatment.

The invention relates to a toadstool bifunctional glycopeptide for targeted immunoregulation and tumor resistance, and belongs to the technical field of biology. The molecular sequence of the morchella glycopeptide provided by the invention is LPS (Fuc) PMLLPQ, and the morchella glycopeptide molecule is obtained by connecting fucose to serine hydroxyl of a peptide chain through an alpha-glucosidic bond in an O-connection glycosylation mode. The morchella glycopeptide is identified from a morchella extract obtained by extracting morchella with pectinase by taking morchella as a substrate, is derived from edible mushrooms and is safe to use; the compound can be effectively combined with TLR4 (Toll-like receptor 4), block inflammatory response and effectively combine and inhibit VEGFR2 (vascular endothelial growth factor receptor-2), and has anti-tumor activity; meanwhile, release of LPS-induced macrophage cytokines can be inhibited, and it is further shown that the morchella glycopeptide has immunoregulation and anti-tumor activity.

The invention relates to the technical field of liqueur, in particular to liqueur and a preparation method thereof.The liqueur is prepared by soaking various medicinal and edible raw materials such as kudzuvine roots, rice, barbary wolfberry fruits, smoked plums, grapes, mulberries, poria cocos, Chinese yams, rhizoma polygonati, jujubes and ginseng in baijiu base liquor according to a specific proportion. According to the present invention, the modern analysis technology shows that the wine contains 25 active components such as resveratrol, protocatechuic acid, oleanolic acid, quercetin, kaempferol and the like, and the components achieve the synergistic effect, such that the product has effects of tumor resistance, liver protection, blood sugar reduction, blood fat reduction, oxidation resistance, inflammation resistance, nerve protection and other health-care functions, and the product has characteristics of definite component, synergistic effect, high safety, and no toxic-side effect. The preparation process is stable and controllable, and is suitable for large-scale production.

The invention discloses a metal nano-material and a preparation method and application thereof in tumor resistance, and relates to the field of metal nano-materials, linoleic acid modified polydopamine coated nano-iron metal nano-materials are constructed by taking nano-iron as a core, coating a polydopamine layer and modifying linoleic acid, the preparation method is simple and convenient to operate, the condition is mild, the cost is low, and the metal nano-material is suitable for industrial production. The repeatability is good. And in the application of tumor treatment, excellent performance is shown. Due to the photo-thermal performance, local high temperature can be generated under irradiation of near-infrared light, tumor cells are directly killed, and drug release is promoted; the nano iron powder participates in an iron death process, and cooperates with linoleic acid to promote lipid peroxide accumulation and activate an iron or copper death pathway; linoleic acid can also improve the anti-tumor function of CD8 + T cells through metabolic reprogramming, and efficient cooperation of photothermal therapy, ferroptosis and immunotherapy is achieved. The material effectively overcomes the limitation of traditional single treatment, remarkably improves the treatment effect, reduces the side effects of the whole body, and provides an innovative solution for multi-mode combined treatment of tumors.

The present disclosure is directed to the interplay between tumor associated macrophages (TAMs) and tumor cells in the TME. SLC13A3 is demonstrated as a transporter for itaconate in tumor cells and plays a previously unreported role in tumor resistance to ferroptosis and ICB. Compositions and methods for blocking the function of SLC13A3's tumor protecting function are described.

The invention discloses a bridged biquinoline compound and a preparation method and application thereof.The compound has a certain killing effect on colon cancer cells, lung cancer cells, liver cancer cells, gastric cancer cells, cervical cancer cells and breast cancer cells, the killing effect on the colon cancer cells is especially obvious, and the killing effect on the colon cancer cells is remarkably superior to that of positive control drugs chloroquine and cis-platinum; in addition, the bridged biquinoline compound has small toxic and side effects, solves the problem of large toxic and side effects of traditional platinum antitumor drugs such as cis-platinum and the like, and can be prepared into antitumor drugs for application. The preparation method of the bridged biquinoline compound is simple and efficient, industrial production can be realized, and the bridged biquinoline compound has great application value in tumor resistance.

Disclosed are a lactylated NBS1 protein and uses thereof. A lactylation site in this application is lysine at position 388 of NBS1 protein. Lactylation at K388 site of the NBS1 protein activates the DNA repair pathway and has multiple functions, including promoting radiotherapy and chemotherapy resistance in tumor cells and enhancing homologous recombination in DNA repair. By targeted inhibition of the lactylated NBS1 protein, tumor resistance to radiotherapy or chemotherapy can be reversed, providing a potential target for reversing tumor resistance to radiotherapy or chemotherapy.

The invention belongs to the field of medicines, and discloses a preparation method of a benzodioxane compound and application of the benzodioxane compound in resisting tumors, chronic inflammation and autoimmune diseases. According to the invention, catechol is used as a raw material, and total 29 benzodioxane compounds are synthesized. The synthesis method disclosed by the invention is simple, simple and convenient in steps and easy in reaction control, and has important reference and practical values for preparing the compound on a large scale. A plurality of prepared compounds have a remarkable IL-6 / STAT3 channel inhibition effect, have an inhibition rate equivalent to that of a positive drug, and can become potential anti-tumor, anti-chronic inflammation and anti-autoimmune disease drugs.

The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a combination of kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose and E-6-O-p-coumaroylpaederoside methyl ester in tumor resistance or the preparation of an anti-tumor drug. The research of the present invention has shown that both a kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose compound monomer and an E-6-O-p-coumaroylpaederoside methyl ester compound monomer have very strong anti-tumor activity. In the in-vivo anti-tumor activity research, the inhibition rates thereof can reach 48.97% and 45.96%, respectively; and when both are combined to inhibit tumor cells, the research reveals that the two monomers have an obvious effect of synergistically inhibiting tumors.

The invention belongs to the field of biological medicine, and particularly relates to a preparation method of a multi-component nano-drug based on a ruthenium complex and application of the multi-component nano-drug in tumor resistance. The preparation method is characterized in that a solvent-anti-solvent method is adopted, a ruthenium complex and various active drugs are self-assembled and combined by means of weak interaction among molecules, and the carrier-free full-active multi-component nano-drug is constructed. The nano-drug is loaded with two synergistic drugs, namely a phototherapy drug ruthenium complex, an oxidative stress amplifying agent cinnamyl aldehyde and a DNA repair inhibitor olaparib. The nano-drug preparation is uniform and stable, can be stored for a long time, is high in biological safety, and can effectively solve the problems that the ruthenium complex is poor in water solubility and low in bioavailability, and drug resistance is easily caused by single medication. Meanwhile, by means of the synergistic effect of multiple drugs, the multi-component nano-drug further strengthens the anti-tumor effect, and a new thought can be provided for developing a safe and efficient tumor treatment strategy.

The present invention relates to an anti-HER3 antibody or its antigen-binding fragment, and an antibody-drug conjugate linked to the antibody, a method for preparing the same, and its use in tumor resistance. The antibody-drug conjugate has a structure represented by Ab-(LD)n and is covalently linked to an effective cytotoxic load via a linker. The anti-HER3 antibody or its antigen-binding fragment and the antibody-drug conjugate are used in the preparation of therapeutic agents for the diagnosis, prevention, and treatment of tumor diseases.

The invention relates to an anti-prothrombin / phosphatidylserine antibody, a pharmaceutical composition and an application of the anti-prothrombin / phosphatidylserine antibody. The anti-prothrombin / phosphatidylserine antibody provided by the invention is connected with a prothrombin / phosphatidylserine compound with high affinity, so that the antibody is combined with phosphatidylserine in a targeted manner to achieve the treatment of tumor resistance, infection resistance, thrombosis resistance, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease and Parkinson's disease.

The invention provides an application of an immunomodulator in tumor resistance, and belongs to the technical field of traditional Chinese medicines. The invention provides a preparation method of nitraria tangutorum polysaccharide, the prepared nitraria tangutorum polysaccharide and application of the nitraria tangutorum polysaccharide as an immunomodulator. The nitraria tangutorum polysaccharide and a PD-1 antibody are combined for use, and the anti-tumor effect of the PD-1 antibody can be enhanced through dual mechanisms of immunoregulation and flora regulation. The nitraria tangutorum polysaccharide and IFN-gamma are combined for use, so that the polarization effect of RAW264.7 cells to M1 type can be promoted, the secretion of IL-1beta, IL-6 and TNF-alpha can be obviously promoted, and the secretion of IL-10 can be inhibited. The Nitraria tangutorum Bobr polysaccharide is combined with the PD-1 antibody, so that the growth speed of tumors can be obviously reduced.

The invention discloses a mitochondrial targeting peptide AMP and an application thereof in tumor resistance, and belongs to the technical field of biological medicines. The amino acid sequence of the mitochondrial targeting peptide AMP is shown as SEQ ID NO.1, and the mitochondrial targeting peptide AMP is formed by connecting an epidermal growth factor receptor (EGFR) targeting peptide GE11 and a mitochondrial toxic peptide KLA through a linker GSGS; the targeting peptide AMP is combined with EGFR on the surface of a tumor cell through GE11 and enters the cell through endocytosis, a KLA module destroys mitochondrial membrane potential, reactive oxygen species (ROS) accumulation and lipid peroxidation are triggered, and ferroptosis is induced. The AMP shows remarkable anti-tumor activity and good biological safety in vivo and in vitro, and a new strategy is provided for colon cancer treatment.

The invention belongs to the field of biology, and particularly relates to a human colon cancer drug-resistant cell strain and application thereof. The human colon cancer cell drug-resistant cell strain is constructed for the first time, and can be used for researching a molecular mechanism of a tumor on drug resistance of a topoisomerase I inhibitor and a method for reversing tumor drug resistance, screening other anti-tumor drugs, discovering tumor drug-resistant markers, screening and evaluating novel anti-tumor drugs and the like. The method has high scientific research and production application values.

The invention relates to a method for producing an anthraquinone compound by using actinomycetes Nocardiopsis aegyptia HDN19-252, and a preparation method of the anthraquinone compound. The invention also relates to an application of the compound in tumor resistance. The structural formula is shown in the specification. A fermentation product containing the compound can be obtained through fermentation culture of actinomycetes Nocardiopsis aegyptia HDN19-252, and then the compound is obtained through separation and purification by adopting normal-phase silica gel column chromatography, reversed-phase C-18 column chromatography, semi-preparative HPLC (High Performance Liquid Chromatography) and other methods. The invention aims to provide a novel compound which is novel in structure and has human metastatic pancreatic adenocarcinoma cell (AsPC-1) inhibitory activity from secondary metabolites derived from actinomycetes, and the compound can be used as a novel pancreatic cancer cell inhibitor for treating pancreatic cancer.

The invention belongs to the field of biological medicines, and particularly relates to a Psammulin A and podophyllotoxin spliced compound and application thereof in preparation of a medicine for treating tumors. The compound is a compound as shown in a formula (I), a derivative, and pharmaceutically acceptable salt or hydrate thereof. The spliced compound is applied to the fields of preparation and tumor resistance; the invention also relates to application of the compound in preparation of drugs for resisting paclitaxel-resistant tumors. The invention also relates to application of the compound in anti-osimertinib drug-resistant tumors. The intracellular activity of the spliced compound disclosed by the invention is superior to that of Psammulin A and etoposide, and the spliced compound has no cross resistance with paclitaxel and osimertinib.

The present invention discloses an intelligent responsive copper-death nanomedicine, its preparation and anti-tumor application. The intelligent responsive copper-death nanomedicine is obtained by loading a copper ion carrier in an intelligent responsive nanocarrier. The intelligent responsive nanocarrier uses copper nanoparticles as the core, and its outer layer is wrapped with a shell of organic mesoporous silica containing X-ray responsive double bonds, and the shell is modified with an acid-responsive polymer. The intelligent responsive nanocarrier has multiple responsive stimulation effects, which can change the charge carried by the drug-carrying system and increase the amount of drug administered into the cell; and has a drug delivery system with good targeting and spatiotemporal controlled release, which can reduce the toxic and side effects of drug molecules on other normal tissues and achieve precise treatment of tumors. The intelligent responsive copper-death nanomedicine can combine the metabolic therapy controlled by copper death with immunotherapy, which will effectively improve tumor resistance, reduce the side effects of radiotherapy on the whole body, and improve the survival rate of patients.